Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $35.00

Jade Biosciences (NASDAQ:JBIO) had its price objective boosted by HC Wainwright from $25.00 to $35.00 in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Jade Biosciences’ Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.52) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.09) EPS.

A number of other brokerages also recently issued reports on JBIO. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research report on Monday, December 29th. Lifesci Capital raised Jade Biosciences to a “strong-buy” rating in a report on Friday, March 6th. Zacks Research downgraded Jade Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Guggenheim raised their price target on Jade Biosciences from $17.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, BTIG Research boosted their price target on Jade Biosciences from $28.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Jade Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Jade Biosciences Stock Down 4.0%

NASDAQ JBIO opened at $13.39 on Wednesday. The company has a market capitalization of $660.39 million, a P/E ratio of -2.91 and a beta of 1.03. Jade Biosciences has a 12-month low of $6.57 and a 12-month high of $100.10. The firm has a 50-day moving average price of $14.67 and a two-hundred day moving average price of $12.54.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Friday, March 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. acquired a new stake in shares of Jade Biosciences in the 2nd quarter valued at $17,703,000. Geode Capital Management LLC acquired a new position in shares of Jade Biosciences during the 2nd quarter worth $6,759,000. Affinity Asset Advisors LLC acquired a new position in shares of Jade Biosciences during the 2nd quarter worth $653,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Jade Biosciences during the 2nd quarter worth $71,000. Finally, XTX Topco Ltd bought a new stake in shares of Jade Biosciences during the 2nd quarter worth $257,000.

Jade Biosciences News Roundup

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $35.00 price target, showing continued analyst conviction and providing a clear upside reference for investors.
• Positive Sentiment: Media coverage highlights the analyst optimism (expectation of a share rise), reinforcing the bullish narrative from HC Wainwright. Jade Biosciences (NASDAQ:JBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: HC Wainwright published detailed quarterly and annual EPS forecasts for 2026–2027 (typical biotech coverage data): ~($0.50) per quarter through 2026–2027 and FY2026/FY2027 EPS around ($2.02)/($2.09). These figures are useful for financial modeling and cash‑runway assumptions.
• Negative Sentiment: HC Wainwright lowered several near‑term EPS estimates: Q1 2026 cut from ($0.41) to ($0.50), Q2 2026 from ($0.42) to ($0.50), Q3 2026 from ($0.44) to ($0.51), Q4 2026 from ($0.46) to ($0.51). Those downgrades signal weaker near‑term operating or development visibility and are a likely driver of the share weakness.
• Negative Sentiment: The firm also reduced FY estimates (FY2026 from ($1.74) to ($2.02); FY2027 from ($2.05) to ($2.09)), increasing expected losses and pressure on near‑term valuation metrics.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.